BGLC — Bionexus Gene Lab Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	C2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1.09	0.752	-0.356	-2.63	-1.6
Depreciation
Non-Cash Items	-0.735	0.029	-0.017	1.13	-0.855
Unusual Items
Other Non-Cash Items
Changes in Working Capital	0.102	-0.862	0.833	0.118	0.115
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	0.553	0.009	0.552	-1.3	-2.23
Capital Expenditures	-0.422	-0.003	-0.054	-0.149	-0.227
Purchase of Fixed Assets
Other Investing Cash Flow Items	1.74	-0.487	-0.396	-0.233	0.645
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	1.32	-0.491	-0.451	-0.383	0.418
Financing Cash Flow Items	0	-0.002	-0.008	0.004	0.004
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-0.005	-0.028	0.108	5.75	0.145
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	1.93	-0.664	-0.005	3.81	-1.63